Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (
Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the
The US FDA has approved a human papillomavirus (HPV) self-sampling solution developed by Roche that allows patients to collect a sample themselves in a healthcare setting.
Bayer’s first-quarter results update shows that its workforce has declined by more than 1,500 full-time equivalent (FTE) employees since the end of last year, suggesting r
Sanofi will invest more than €1 billion ($1.08 billion) in new bioproduction capacity at three manufacturing sites in France as part of a €3.5 billion programme in the cou
AstraZeneca easily delivered on chief executive Pascal Soriot’s pledge to deliver $45 billion in revenues by 2023, set a decade earlier as he fended off a takeover bid by
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.